Interim analysis of COVID-19 vaccine effectiveness against
Severe Acute Respiratory Infection due to laboratory-confirmed
SARS-CoV-2 among individuals aged 50 years and older, ECDC
multi-country study – first update

x 2022

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update

BACCI, Sabrina and Nathalie NICOLAY

Basic information

Original name

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update

Authors

BACCI, Sabrina and Nathalie NICOLAY

Edition

2022

Publisher

FNUSA, ECDC

Other information

Language

English

Type of outcome

Projekty výzkumu a vývoje

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Sweden

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

COVID-19

RIV identification code

RIV/00216224:14110/22:00127691

Organization unit

Faculty of Medicine

Keywords (in Czech)

Technical Report; COVID-19; SARI

Keywords in English

Technical Report; COVID-19; SARI

Abstract

V originále

Evaluating the real-world performance of COVID-19 vaccines is critical to understanding the risks and benefits of COVID-19 vaccination programmes. ECDC has been building infrastructure to allow regular monitoring of COVID-19 vaccine effectiveness over time, using a multi-country approach that involves studies implemented in different settings across EU/EEA countries. The project allows for progressive inclusion of more countries over time and the same generic protocol is used across all countries. This update reports on a multi-country study that aims to estimate vaccine effectiveness against severe COVID-19 disease, by assessing it in individuals hospitalised for SARI. This ECDC hospital vaccine effectiveness study began at the end of 2020 and, as of 25 October 2021, has recruited 10 participating countries across the EU/EEA (Belgium, Croatia, Czechia, France, Greece, Ireland, Luxembourg, Malta, Portugal and Spain), including 42 hospitals among them (ranging from 1 to 13 hospitals per country). Five countries began their vaccination campaigns at the end of December 2020 and five in early January 2021. The analysis presented in this report aims to estimate vaccine effectiveness among SARI patients aged 50 years and older, from the first vaccination campaign start date on 27 December 2020 up to and including 30 June 2021. This end date was selected to provide a study period before wide circulation of the Delta variant of concern (VOC) in the European region.

Links

90128, large research infrastructures

Name: CZECRIN III

Citovat

BACCI, Sabrina and Nathalie NICOLAY. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update. FNUSA, ECDC, 2022.

@misc{2243543,
   author = {Bacci, Sabrina and Nicolay, Nathalie},
   keywords = {Technical Report; COVID-19; SARI},
   language = {eng},
   publisher = {FNUSA, ECDC},
   title = {Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update},
   url = {https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-of-COVID-19-vaccine-effectiveness-against-SARI-2022.pdf},
   year = {2022}
}

TY  - JFULL
ID  - 2243543
AU  - Bacci, Sabrina - Nicolay, Nathalie
PY  - 2022
TI  - Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update
PB  - FNUSA, ECDC
KW  - Technical Report
KW  - COVID-19
KW  - SARI
UR  - https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-of-COVID-19-vaccine-effectiveness-against-SARI-2022.pdf
N2  - Evaluating the real-world performance of COVID-19 vaccines is critical to understanding the risks and benefits of COVID-19 vaccination programmes. ECDC has been building infrastructure to allow regular monitoring of COVID-19 vaccine effectiveness over time, using a multi-country approach that involves studies implemented in different settings across EU/EEA countries. The project allows for progressive inclusion of more countries over time and the same generic protocol is used across all countries. This update reports on a multi-country study that aims to estimate vaccine effectiveness against severe COVID-19 disease, by assessing it in individuals hospitalised for SARI. This ECDC hospital vaccine effectiveness study began at the end of 2020 and, as of 25 October 2021, has recruited 10 participating countries across the EU/EEA (Belgium, Croatia, Czechia, France, Greece, Ireland, Luxembourg, Malta, Portugal and Spain), including 42 hospitals among them (ranging from 1 to 13 hospitals per country). Five countries began their vaccination campaigns at the end of December 2020 and five in early January 2021. The analysis presented in this report aims to estimate vaccine effectiveness among SARI patients aged 50 years and older, from the first vaccination campaign start date on 27 December 2020 up to and including 30 June 2021. This end date was selected to provide a study period before wide circulation of the Delta variant of concern (VOC) in the European region.
ER  -

BACCI, Sabrina and Nathalie NICOLAY. \textit{Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update}. FNUSA, ECDC, 2022.

Detailed Information on Publication Record